Renal Cell Cancer Update
Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:45:45
- Mais informações
Informações:
Sinopse
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPROTACmBC24).
